Sequana Medical announces the appointment of Kirsten Van Bockstaele as Chief Financial Officer
Zurich, Switzerland: 12 July 2018 - Sequana Medical AG, a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today the appointment of Kirsten Van Bockstaele as Chief Financial Officer, with immediate effect. Kirsten is a seasoned finance executive with extensive international experience in the healthcare industry.
Kirsten joins Sequana Medical from Fagron (formerly Arseus), an international pharmaceutical compounding company. Within Fagron, she held a number of senior financial roles, most recently as Vice President of Finance, North America. In this role, Kirsten was responsible for creating and overseeing the company's financial strategy and policy, positioning Fagron's North American companies for growth. She also played a pivotal role in building out the North American headquarters, supporting the financial integration of acquisitions and assisting in redirecting the company's strategy.
More info on Sequana's website.
Previous > Mainstay Medical announces the completion of all implants in the ReActiv8-B Study